Glycoprotein S3
Alternative Names: gp S3Latest Information Update: 25 Jun 1998
At a glance
- Originator Kureha Corporation
- Class Antineoplastics
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jun 1998 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 03 Jul 1997 New profile
- 03 Jul 1997 Preclinical development for Cancer in Japan (Unknown route)